The European electrical ablation market, mainly driven by the increasing aging population with higher risk of chronic disease and increasing age-related chronic diseases was valued at $208.0 million in 2013 and is expected to reach $249.0 million by 2018. In the European electrical ablation market, electrical ablators accounted for a share of 90.4% in 2011.
Tachycardia and atrial arrhythmia occur in people where cardiac electrical impulses move abnormally through a deviated path involving extra tissue. This impulse creates an abnormal pattern of elevated or decreased heartbeats in a patient. Electrical ablation is used for such conditions and involves ablating healthy cells so as to cut off electrical impulses that are causing the uneven heartbeats. The procedure can be done percutaneously or by minimally invasive techniques using ultrasound imaging, fluoroscopy, or MRI.
The report on the European electrical ablation market analyzes the market by segments such as electrical ablators and electronic brachytherapy. The high success rate (above 70%) for removal of arrhythmic heart conditions is the major factor that is driving this market. There are over 14 million arrhythmia cases with fatality rates of 15% annually. It affects over 10% of the population over the age of 80 globally. This rate of increase in heart conditions is predicted to sustain the electrical ablation technology market through 2016, by a CAGR of 5.2%.
The European market is challenging as it is a heterogeneous region in terms of regulatory and reimbursement approaches, with every country having its own unique characteristics. Recent trends show an increased inclination of companies towards Europe for the development and launch of their preliminary products. In addition, it is observed that capital investment required for regulatory approval of a product is significantly less than that compared to the U.S. Ultimately, market players are adopting a strategy to launch their products initially in Europe, as it offers an opportunity to balance the risk-to-reward ratio in case of innovative technologies.
Traditional electric ablation probes are not effective for ablating certain tissue types such as adhesions which develop in a large fraction of patients after surgery. Thus, there is an unmet need for devices that are suitable for ablating a variety of abnormal tissues, adhesions, and fibrous growths. Minimally invasive surgical devices are yet another area of expansion for market players in the ablation technologies market.
The report also provides an extensive competitive landscape of companies operating in the European electrical ablation market. The main companies extensively covered in this report are ConMed Corporation (U.S), Medtronic (U.S), Boston Scientific Corporation (U.S), AngioDynamics (U.S), and Covidien plc (Ireland).
The details of segment and country-specific company shares, news and deals, mergers and acquisitions, segment-specific pipeline products, product approvals, and product recalls of the major companies have also been covered in the report.
Report Customization Options
Along with market data, you can also customize MMM offerings that are in keeping with your company’s specific needs. Customize your report on the European electrical ablation market for to get an insight into all-inclusive industry standards and a deep-dive analysis of the following considerations:
- Usage pattern (in-depth trend analysis) of products (segment wise)
- Product matrix which gives a detailed comparison of the product portfolio of each company mapped at country and sub-segment level
- End-user adoption rate analysis of the products (segment wise and country wise)
- Comprehensive coverage of product approvals, pipeline products, and product recalls
- Country-specific prevalence of cancer, cardiovascular disorders, gynecological disorders, and orthopedic disorders
- Country-specific patient pool of cancer, cardiovascular disorders, gynecological disorders, and orthopedic disorders
- Disease progression (pattern analysis)
Surgeon/Physician Perception Analysis
- Fast turnaround analysis of surgeons’ response to market events and trends
- Surgeons’ opinion about products from different companies
- Surgeons’ qualitative inputs on epidemiology data
Brand/Product Perception Matrix
- Comprehensive study of customers perception and behavior through our inbuilt social connection tool checking the virality and tonality of blogs
- Analysis of overall brand usage and familiarity and brand advocacy distribution
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
Americas Thermal Ablation
The American Thermal Ablation Market was pegged at $3097 million in 2013 and expected to be $5012 million by 2018. The main companies operating in thermal ablation market and extensively covered in this report are Varian Medical systems, Elekta, Biosense Webster, St. Jude Medical Boston Scientfic, Accuray, Medtronic, CR Bard, Others
Asia-Pacific Thermal Ablation
The Asia-Pacific Thermal Ablation Market was pegged at $1533 million in 2013 and expected to be $2772 million by 2018. The main companies operating in Asia-Pacific Thermal Ablation market and extensively covered in this report are Varian Medical systems, Elekta, Biosense Webster, St. Jude Medical Boston Scientfic, Accuray, Medtronic, CR Bard, Others.
European Thermal Ablation
The European Thermal Ablation Market was pegged at $2132 million in 2013 and expected to be $3328 million by 2018. The main companies operating in European thermal ablation market and extensively covered in this report are Varian Medical systems, Elekta, Biosense Webster, St. Jude Medical Boston Scientfic, Accuray, Medtronic, CR Bard, Others.